清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy

医学 奥沙利铂 内科学 回顾性队列研究 化疗 吉西他滨 胃肠病学 无进展生存期 队列 肝动脉灌注 癌症 外科 肿瘤科 结直肠癌
作者
Darren Cowzer,Kevin C. Soares,Henry S. Walch,Mithat Gönen,Taryn Mary Boucher,Richard K G Do,James J. Harding,Anna M. Varghese,Diane L. Reidy‐Lagunes,Leonard B. Saltz,Louise Catherine Connell,Ghassan K. Abou‐Alfa,Alice Chia-Chi Wei,Nikolaus D. Schultz,T. Peter Kingham,Michael Ian D'Angelica,Jeffrey A. Drebin,Vinod P. Balachandran,Francisco Sánchez-Vega,Nancy E. Kemeny
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:117 (2): 279-286 被引量:12
标识
DOI:10.1093/jnci/djae202
摘要

BACKGROUND: Hepatic artery infusion of chemotherapy has demonstrated disease control and suggested improvement in overall survival in intrahepatic cholangiocarcinoma. We report herein the long-term results and role of molecular alterations of a phase II clinical trial of hepatic artery infusion chemotherapy plus systemic chemotherapy, with a retrospective cohort of patients treated with hepatic artery infusion at Memorial Sloan Kettering Cancer Center. METHODS: This is a secondary analysis of a single-institution, phase II trial, and retrospective cohort of unresectable intrahepatic cholangiocarcinoma treated with hepatic artery infusion floxuridine plus systemic gemcitabine and oxaliplatin. The primary aim was to assess long-term oncologic outcomes. A subset underwent tissue-based genomic sequencing, and molecular alterations were correlated with progression-free survival (PFS) and overall survival. RESULTS: A total of 38 patients were treated on trial with a median follow-up of 76.9 months. Median PFS was 11.8 months (95% confidence interval [CI] = 11 to 15.1 months). The median overall survival was 26.8 months (95% CI = 20.9 to 40.6 months). The 1-, 2-, and 5-year overall survival rate was 89.5%, 55%, and 21%, respectively. Nine (24%) patients received hepatic artery infusion with mitomycin C post-floxuridine progression with an objective response rate of 44% and a median PFS of 3.93 months (95% CI = 2.33 months to not reached). A total of 170 patients not treated on the clinical trial were included in a retrospective analysis. Median PFS and overall survival were 7.93 months (95% CI = 7.27 to 10.07 months) and 22.5 months (95% CI = 19.5 to 28.3 months), respectively. Alterations in the TP53 and cell-cycle pathway had a worse PFS to hepatic artery infusion-based therapy compared with wild-type disease. CONCLUSION: In locally advanced intrahepatic cholangiocarcinoma, hepatic artery infusion with floxuridine in combination with systemic therapy can offer long-term durable disease control. Molecular alterations may predict for response.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被Gilgardea采纳,获得10
2秒前
汉堡包的应助被辅助但上分采纳,获得10
12秒前
忧郁凝阳完成签到,获得积分10
20秒前
整齐成协完成签到,获得积分10
25秒前
33秒前
冥土追魂完成签到,获得积分10
34秒前
冥土追魂发布了新的文献求助10
37秒前
丘比特的应助被武雨寒采纳,获得10
48秒前
懵懂的小之完成签到,获得积分10
48秒前
专注的怜珊完成签到,获得积分10
50秒前
完美世界的应助被武雨寒采纳,获得10
55秒前
科研通AI6.4的应助被cat采纳,获得10
1分钟前
1分钟前
羞涩的傲菡完成签到,获得积分10
1分钟前
武雨寒发布了新的文献求助10
1分钟前
兴奋乞完成签到,获得积分10
1分钟前
零度空间完成签到,获得积分10
1分钟前
痴情的不惜完成签到,获得积分10
1分钟前
1分钟前
整齐念薇完成签到,获得积分10
1分钟前
武雨寒发布了新的文献求助10
1分钟前
1分钟前
诸葛平卉完成签到 ,获得积分10
1分钟前
星辰大海的应助被psm采纳,获得10
1分钟前
1分钟前
飞天大南瓜完成签到,获得积分10
1分钟前
Gilgardea发布了新的文献求助10
2分钟前
车车完成签到 ,获得积分10
2分钟前
精明开山完成签到,获得积分10
2分钟前
2分钟前
鲤鱼遥完成签到,获得积分10
2分钟前
cat发布了新的文献求助10
2分钟前
AG完成签到,获得积分10
2分钟前
田田完成签到 ,获得积分10
2分钟前
2分钟前
等待凡英完成签到,获得积分10
2分钟前
陈荆洲完成签到,获得积分10
2分钟前
高高的玉兰完成签到,获得积分10
2分钟前
2分钟前
小二郎的应助被cat采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166413
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750478
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473835